Abstract
There is extensive trial-based evidence showing that antihypertensive drugs reduce the risk of vascular events (e.g. stroke and myocardial infarction) as well as target organ damage (e.g. left ventricular hypertrophy and microalbuminuria). However, some of these benefits appear to be, at least partially, independent of the extent of blood pressure (BP) lowering. It is also evident that in certain clinical situations some antihypertensive drugs are more effective than others. In this review we discuss the effects of antihypertensive drugs on the endothelium, platelets, fibrinolysis and coagulation. These properties may account for the observed BP-independent actions. Antihypertensive drugs exert multiple effects on the vascular endothelium. These include effects on nitric oxide (NO) and angiotensin II-mediated actions. Many BP lowering drugs can inhibit platelet activity, although the relevance of this property is unknown, especially if patients are also taking platelet inhibitors (e.g. aspirin). Antihypertensive drugs also influence fibrinolysis and coagulation. These effects may be mediated by a variety of mechanisms, including altering insulin sensitivity. The haemostatic actions of antihypertensive drugs deserve greater recognition and further investigation.
Keywords: angiotensin, antihypertensive drugs, coagulation, endothelium, fibrinolysis, haemostasis, nitric oxide, platelets
Current Pharmaceutical Design
Title: The Effects of Antihypertensive Therapy on Haemostatic Parameters
Volume: 9 Issue: 29
Author(s): E. S. Ganotakis, J. A. Papadakis, G. E. Vrentzos and D. P. Mikhailidis
Affiliation:
Keywords: angiotensin, antihypertensive drugs, coagulation, endothelium, fibrinolysis, haemostasis, nitric oxide, platelets
Abstract: There is extensive trial-based evidence showing that antihypertensive drugs reduce the risk of vascular events (e.g. stroke and myocardial infarction) as well as target organ damage (e.g. left ventricular hypertrophy and microalbuminuria). However, some of these benefits appear to be, at least partially, independent of the extent of blood pressure (BP) lowering. It is also evident that in certain clinical situations some antihypertensive drugs are more effective than others. In this review we discuss the effects of antihypertensive drugs on the endothelium, platelets, fibrinolysis and coagulation. These properties may account for the observed BP-independent actions. Antihypertensive drugs exert multiple effects on the vascular endothelium. These include effects on nitric oxide (NO) and angiotensin II-mediated actions. Many BP lowering drugs can inhibit platelet activity, although the relevance of this property is unknown, especially if patients are also taking platelet inhibitors (e.g. aspirin). Antihypertensive drugs also influence fibrinolysis and coagulation. These effects may be mediated by a variety of mechanisms, including altering insulin sensitivity. The haemostatic actions of antihypertensive drugs deserve greater recognition and further investigation.
Export Options
About this article
Cite this article as:
Ganotakis S. E., Papadakis A. J., Vrentzos E. G. and Mikhailidis P. D., The Effects of Antihypertensive Therapy on Haemostatic Parameters, Current Pharmaceutical Design 2003; 9 (29) . https://dx.doi.org/10.2174/1381612033453839
DOI https://dx.doi.org/10.2174/1381612033453839 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Complementary Roles of Imaging and ‘Omics’ for Future Anti-Atherosclerotic Drug Development
Current Pharmaceutical Design Clinical Value of Prostacyclin and its Analogs in the Management of Pulmonary Arterial Hypertension
Current Vascular Pharmacology Monoclonal Antibodies as Cancer Therapeutics
Recent Patents on Biotechnology Peripheral Arterial Disease - The Forgotten Risk Factor
Vascular Disease Prevention (Discontinued) Determinants of Human Coronary Collaterals
Current Cardiology Reviews Biomarkers of Atrial Fibrillation in Metabolic Syndrome
Current Medicinal Chemistry A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes
Current Pharmaceutical Design The Role of Antiplatelet Therapy in Primary Prevention. A Review
Current Pharmaceutical Design The Developmental Origins of Osteoporosis
Current Genomics Prophylaxis of Erectile Function After Radical Prostatectomy with Phosphodiesterase Type 5 Inhibitors
Current Pharmaceutical Design Lipases as Modulators of Atherosclerosis in Murine Models
Current Drug Targets Phytocompounds as Potential Agents to Treat Obesity-Cardiovascular Ailments
Cardiovascular & Hematological Agents in Medicinal Chemistry Endogenous Cardioprotective Agents: Role in Pre and Postconditioning
Current Drug Targets Rheumatoid Arthritis: Cardiovascular Manifestations, Pathogenesis, and Therapy
Current Pharmaceutical Design Present Insights on Cardiomyopathy in Diabetic Patients
Current Diabetes Reviews Therapeutics Targeting Nogo-A Hold Promise for Stroke Restoration
CNS & Neurological Disorders - Drug Targets ESVS Guidelines: Section B - Diagnosis and Investigation of Patients with Carotid Stenosis
Current Vascular Pharmacology Low Activity of Plasminogen Activator: A Common Feature of Non- Iatrogenic Comorbidities of Schizophrenia
CNS & Neurological Disorders - Drug Targets The Stress Response: Implications for the Clinical Development of Hsp90 Inhibitors
Current Cancer Drug Targets The Brain, the Penis and Steroid Hormones: Clinical Correlates with Endothelial Dysfunction
Current Pharmaceutical Design